Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

LSC 2

Next Previous
Search
Drug Profile

LSC 2

Alternative Names: ABCB5+ limbal stem cells - RHEACELL; LSC-2

Latest Information Update: 07 Jul 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator RHEACELL
  • Class Eye disorder therapies; Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Limbal stem cell deficiency
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Limbal stem cell deficiency

Most Recent Events

  • 07 Jun 2022 RHEACELL discontinues a phase I/II trial in Limbal stem cell deficiency in USA and Germany (Topical) (NCT03549299)
  • 26 Sep 2020 Ticeba in-licenses US and European patents from The Brigham and Women's Hospital covering the ABCB5+ stem cell technology, prior to September 2020 (Ticeba website, September 2020)
  • 25 Sep 2020 RHEACELL in-licenses patent portfolio related to ABCB5 from Childrens Hospital Boston, before September 2020 (RHEACELL website, September 2020)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top